Table 2.
Univariate analysis of OS and DFS.
| Variables | OS | DFS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age | 1.02 (0.98,1.21) | 0.258 | 1.08 (0.88,1.32) | 0.267 |
| Gender (Male vs. Female) | 1.11 (0.72,1.52) | 0.324 | 1.05 (0.94,1.11) | 0.451 |
| ASA score (1 vs. 2. vs. 3) | 1.05 (0.70,1.46) | 0.159 | 1.11 (0.98,1.16) | 0.298 |
| CCI (0 vs.1 vs. ≧2) | 1.15 (0.64,1.20) | 0.267 | 1.26 (1.08,1.61) | 0.187 |
| Tumour differentiation (Poor) | 2.10 (1.71,2.76) | <0.001 | 2.34 (1.58,2.65) | <0.001 |
| Nerve invasion (Yes) | 1.52 (1.24,1.75) | <0.001 | 1.63 (1.35,1.81) | <0.001 |
| AJCC TNM stage (I vs. II vs. III) | 1.45 (0.93,1.71) | 0.254 | 1.34 (0.98,1.71) | 0.186 |
| Postoperative Chemotherapy (No) | 1.42 (1.29,1.58) | <0.001 | 1.64 (1.38,1.81) | <0.001 |
| MOR expression (high) | 1.12 (0.94,1.46) | 0.078 | 1.18 (0.97,1.24) | 0.175 |
BMI, Body Mass Index; IQR, Inter Quartile Range; ASA, American Society of Anaesthesiologists score; CCI, Charlson Comorbidity Index; AJCC 8th TNM stage, American Joint Committee on Cancer the 8th edition; OS, Overall Survival; DFS, Disease free Survival; MOR, Mu-Opioids Receptor.